D-Index & Metrics Best Publications

Masafumi Fukagawa

Tokai University
Japan

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 71 Citations 17,718 605 World Ranking 17008 National Ranking 556

Overview

What is he best known for?

The fields of study Masafumi Fukagawa is best known for:

Gene
Enzyme
Diabetes mellitus

His Secondary hyperparathyroidism study focuses on Cinacalcet and Calcimimetic. His Kidney disease research incorporates elements of Kidney and Renal function. In his research, he undertakes multidisciplinary study on Kidney and Kidney disease. He performs integrative study on Internal medicine and Surgery. Masafumi Fukagawa conducts interdisciplinary study in the fields of Endocrinology and Diabetes mellitus through his research. His Calcium study frequently draws connections to other fields, such as Cinacalcet. He performs integrative study on Parathyroid hormone and Fibroblast growth factor 23 in his works. Masafumi Fukagawa performs multidisciplinary study in the fields of Hyperparathyroidism and Calcitriol via his papers. Masafumi Fukagawa applies his multidisciplinary studies on Calcitriol and Hyperparathyroidism in his research.

His most cited work include:

Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters (616 citations)
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency (291 citations)
p -Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase (248 citations)

What are the main themes of his work throughout his whole career to date

A component of his Secondary hyperparathyroidism study involves Cinacalcet and Calcimimetic. He conducts interdisciplinary study in the fields of Calcimimetic and Secondary hyperparathyroidism through his works. Masafumi Fukagawa conducts interdisciplinary study in the fields of Internal medicine and Surgery through his works. He brings together Surgery and Internal medicine to produce work in his papers. Endocrinology connects with themes related to Oxidative stress in his study. Calcium is often connected to Hyperphosphatemia in his work. His research on Hyperphosphatemia frequently links to adjacent areas such as Calcium. With his scientific publications, his incorporates both Parathyroid hormone and Cinacalcet. He performs integrative Kidney disease and Hyperparathyroidism research in his work.

Masafumi Fukagawa most often published in these fields:

Internal medicine (95.72%)
Endocrinology (64.14%)
Calcium (51.97%)

What were the highlights of his more recent work (between 2019-2022)?

Internal medicine (100.00%)
Endocrinology (60.00%)
Kidney disease (56.67%)

In recent works Masafumi Fukagawa was focusing on the following fields of study:

Masafumi Fukagawa is doing genetic studies as part of his Hyperphosphatemia and Renal osteodystrophy and Kidney disease investigations. He undertakes interdisciplinary study in the fields of Renal osteodystrophy and Secondary hyperparathyroidism through his research. His research on Internal medicine often connects related topics like Interquartile range. His Endocrinology study frequently draws connections to other fields, such as Kidney. He undertakes interdisciplinary study in the fields of Kidney and Kidney disease through his research. Masafumi Fukagawa undertakes interdisciplinary study in the fields of Hemodialysis and Dialysis through his works. Masafumi Fukagawa combines Dialysis and Secondary hyperparathyroidism in his studies. Masafumi Fukagawa undertakes interdisciplinary study in the fields of Parathyroid hormone and Hyperparathyroidism through his works. He undertakes multidisciplinary studies into Hyperparathyroidism and Parathyroid hormone in his work.

Between 2019 and 2022, his most popular works were:

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine (31 citations)
Prevalence of chronic kidney disease in Asia: a systematic review and analysis (29 citations)
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS (25 citations)

In his most recent research, the most cited works focused on:

Kidney disease
Enzyme
Kidney

His work in Internal medicine is not limited to one particular discipline; it also encompasses Area under the curve. He combines Kidney disease and Nephrotic syndrome in his research. In his research, Masafumi Fukagawa performs multidisciplinary study on Nephrotic syndrome and Kidney disease. He integrates Dialysis with Peritoneal dialysis in his research. Masafumi Fukagawa incorporates Peritoneal dialysis and Dialysis in his research. His Vitamin D and neurology research extends to the thematically linked field of Endocrinology. Much of his study explores Vitamin D and neurology relationship to Endocrinology. By researching both Calcium and Phosphate binder, Masafumi Fukagawa produces research that crosses academic boundaries. He performs multidisciplinary study in Phosphate binder and Parathyroid hormone in his work.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

N Fukuda;H Tanaka;Y Tominaga;M Fukagawa.
Journal of Clinical Investigation (1993)

813 Citations

Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters

Markus Ketteler;Geoffrey A. Block;Pieter Evenepoel;Masafumi Fukagawa.
Kidney International (2017)

708 Citations

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Takashi Shigematsu;Junichiro James Kazama;Takeyoshi Yamashita;Seiji Fukumoto.
American Journal of Kidney Diseases (2004)

375 Citations

p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase

Hiroshi Watanabe;Yohei Miyamoto;Daisuke Honda;Hisae Tanaka.
Kidney International (2013)

327 Citations

Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

Masafumi Fukagawa;Keitaro Yokoyama;Fumihiko Koiwa;Masatomo Taniguchi.
Therapeutic Apheresis and Dialysis (2013)

323 Citations

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients

Hirotaka Komaba;Shunsuke Goto;Hideki Fujii;Yasuhiro Hamada.
Kidney International (2010)

299 Citations

Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Francesca Tentori;Mia Wang;Brian A. Bieber;Angelo Karaboyas.
Clinical Journal of The American Society of Nephrology (2015)

285 Citations

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients

Shohei Nakanishi;Junichiro James Kazama;Tomoko Nii-Kono;Kentaro Omori.
Kidney International (2005)

263 Citations

Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor

Chiaki Hidai;Thomas Zupancic;Kalyani Penta;Kalyani Penta;Adel Mikhail.
Genes & Development (1998)

251 Citations

Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.

Masafumi Fukagawa;Masafumi Kitaoka;Hung Yi;Naoko Fukuda.
Nephron (1994)

235 Citations

If you think any of the details on this page are incorrect, let us know.